1. Chu JH, Feudtner C, Heydon K, Walsh TJ, Zaoutis
TE. Hospitalizations for endemic mycoses: a population-based national
study. Clin Infect Dis. 2006;42(6):822-825.
2. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis
in a tertiary-care cancer center in the era of Aspergillus-active
antifungal therapy: a case-control observational study of 27 recent cases. J
Infect Dis. 2005;191(8):1350-1360.
3. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive
zygomycosis in hematopoietic stem cell transplant recipients receiving
voriconazole prophylaxis. Clin Infect Dis. 2004;39(4):584-587.
4. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough
fungal infections in stem cell transplant recipients receiving voriconazole. Clin
Infect Dis. 2004;39(5):743-746.
5. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after
voriconazole treatment in recipients of hematopoietic stem-cell transplants. N
Engl J Med. 2004;350(9):950-952.
6. Singh N. Antifungal prophylaxis for solid organ transplant
recipients: seeking clarity amidst controversy. Clin Infect
Dis. 2000;31(2):545-553.
7. Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998;26(4):781-803,
quiz 804-805.
8. Denning DW, Marinus A, Cohen J, et al. An EORTC multicentre
prospective survey of invasive aspergillosis in haematological patients: diagnosis
and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative
Group. J Infect. 1998;37(2):173-180.
9. Roy MJ, Walsh TJ. Histopathologic and immunohistochemical
changes in gut-associated lymphoid tissues after treatment of rabbits
with
dexamethasone.
Lab Invest. 1992;66(4):437-443.
10. Ganz T, Weiss J. Antimicrobial peptides of phagocytes and
epithelia. Semin Hematol. 1997;34(4): 343-354.
11. Rosenberg M, Patterson R, Mintzer R, Cooper BJ, Roberts
M, Harris KE. Clinical and immunologic criteria for the diagnosis
of allergic bronchopulmonary aspergillosis. Ann Intern Med. 1977;86(4):405-414.
12. Barloon TJ, Galvin JR, Mori M, Stanford W, Gingrich RD.
High-resolution ultrafast chest CT in the clinical management of
febrile bone marrow transplant patients with normal or nonspecific
chest roentgenograms. Chest. 1991;99(4):928-933.
13. Donowitz GR, Harman C, Pope T, Stewart FM. The role of the
chest roentgenogram in febrile neutropenic patients. Arch
Intern Med. 1991;151 (4):701-704.
14. Korones DN, Hussong MR, Gullace MA. Routine chest radiography
of children with cancer hospitalized for fever and neutropenia:
is it really necessary? Cancer. 1997;80(6):1160-1164.
15. Heussel CP, Kauczor HU, Heussel GE, et al. Pneumonia in
febrile neutropenic patients and in bone marrow and blood stem-cell
transplant recipients: use of high-resolution computed tomography. J
Clin Oncol. 1999;17(3):796-805.
16. Heussel CP, Kauczor HU, Heussel G, Fischer B, Mildenberger
P, Thelen M. Early detection of pneumonia in febrile neutropenic
patients: use of thin-section CT.
AJR Am J Roentgenol. 1997; 169(5):1347-1353.
[PubMed: 9353456]
17. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume
and changing characteristics of invasive pulmonary aspergillosis
on sequential thoracic computed tomography scans in patients with
neutropenia. J Clin Oncol. 2001;19(1):253-259.
18. Caillot D, Casasnovas O, Bernard A, et al. Improved management
of invasive pulmonary aspergillosis in neutropenic patients using
early thoracic computed tomographic scan and surgery. J
Clin Oncol. 1997;15(1):139-147.
19. Weisser M, Rausch C, Droll A, et al. Galactomannan does
not precede major signs on a pulmonary computerized tomographic
scan suggestive of invasive aspergillosis in patients with hematological
malignancies. Clin Infect Dis. 2005;41(8):1143-1149.
20. Kim MJ, Lee KS, Kim J, Jung KJ, Lee HG, Kim TS. Crescent
sign in invasive pulmonary aspergillosis: frequency and related
CT and clinical factors. J Comput Assist Tomogr. 2001;25(2):305-310.
21. Jantunen E, Piilonen A, Volin L, et al. Diagnostic aspects
of invasive Aspergillus infections in allogeneic BMT recipients. Bone
Marrow Transplant. 2000;25(8):867-871.
22. Hwang SS, Kim HH, Park SH, Jung JI, Jang HS. The value of
CT-guided percutaneous needle aspiration in immunocompromised patients with
suspected pulmonary infection. AJR Am J Roentgenol. 2000;175(1):235-238.
23. Hoffer FA, Gow K, Flynn PM, Davidoff A. Accuracy of percutaneous
lung biopsy for invasive pulmonary aspergillosis. Pediatr
Radiol. 2001;31(3):144-152.
24. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C,
Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for
the diagnosis of invasive aspergillosis: variables that affect performance. J
Infect Dis. 2004;190(3):641-649.
25. Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillus
galactomannan detection in the diagnosis of invasive aspergillosis
in cancer patients. J Clin Oncol. 2002;20(7):1898-1906.
26. Maertens J, Van Eldere J, Verhaegen J, Verbeken E, Verschakelen
J, Boogaerts M. Use of circulating galactomannan screening for early
diagnosis of invasive aspergillosis in allogeneic stem cell transplant
recipients. J Infect Dis. 2002;186(9):1297-1306.
27. Kami M, Fukui T, Ogawa S, et al. Use of real-time PCR on
blood samples for diagnosis of invasive aspergillosis. Clin
Infect Dis. 2001;33(9):1504-1512.
28. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines
for the use of antimicrobial agents in neutropenic patients with
cancer. Clin Infect Dis. 2002;34(6):730-751.
29. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment
of candidiasis. Clin Infect Dis. 2004;38(2):161-189.
30. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines
for diseases caused by Aspergillus. Infectious Diseases Society
of America. Clin Infect Dis. 2000;30(4):696-709.
31. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines
for the management of cryptococcal disease. Infectious Diseases
Society of America. Clin Infect Dis. 2000;30(4):710-718.
32. Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. Clin
Infect Dis. 2005;41(9):1217-1223.
33. Chapman SW, Bradsher RW, Jr., Campbell GD, Jr., Pappas PG,
Kauffman CA. Practice guidelines for the management of patients
with blastomycosis. Infectious Diseases Society of America. Clin
Infect Dis. 2000;30(4):679-683.
34. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice
guidelines for the management of patients with histoplasmosis: 2007
update by the Infectious Diseases Society of America. Clin
Infect Dis. 2007;45(7):807-825.
35. Kauffman CA, Hajjeh R, Chapman SW. Practice guidelines for
the management of patients with sporotrichosis. For the Mycoses
Study Group. Infectious Diseases Society of America. Clin
Infect Dis. 2000;30(4):684-687.
36. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality
rate: systematic review of the literature. Clin Infect Dis. 2001;32(3):358-366.
37. Patterson JE, Peters J, Calhoon JH, et al. Investigation
and control of aspergillosis and other filamentous fungal infections
in solid organ transplant recipients. Transpl Infect Dis. 2000;2 (1):22-28.
38. Bradsher RW. Histoplasmosis and blastomycosis. Clin
Infect Dis. 1996;22(suppl 2):S102-S111.
39. Bradsher RW, Rice DC, Abernathy RS.
Ketoconazole therapy
for endemic blastomycosis.
Ann Intern Med. 1985;103(6
Pt 1):872-879.
40. Chapman SW, Lin AC, Hendricks KA, et al. Endemic blastomycosis
in Mississippi: epidemiological and clinical studies. Semin
Respir Infect. 1997;12(3):219-228.
41. Dismukes WE, Bradsher RW, Jr., Cloud GC, et al. Itraconazole
therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study
Group. Am J Med. 1992;93(5):489-497.
42. Pappas PG, Bradsher RW, Chapman SW, et al. Treatment of
blastomycosis with fluconazole: a pilot study. The National Institute
of Allergy and Infectious Diseases Mycoses Study Group. Clin
Infect Dis. 1995;20(2):267-271.
43. Pappas PG, Bradsher RW, Kauffman CA, et al. Treatment of
blastomycosis with higher doses of fluconazole. The National Institute
of Allergy and Infectious Diseases Mycoses Study Group. Clin
Infect Dis. 1997;25(2):200-205.